Sanofi India (SANOFI) Fundamentals 2026 — P/E 25.3x, Revenue Analysis | SniperIQ
Sanofi India (SANOFI) is a India-listed Healthcare company in Drug Manufacturers - General with a market capitalization of ₹7,751 Crore, trading at ₹3403.50 on the BSE. This SniperIQ fundamentals page covers Sanofi India's valuation (P/E 25.3x, P/B 10.5x), profitability (net margin 17.5%), revenue (₹1,837 Crore in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Sanofi India's market cap?
Sanofi India (SANOFI) has a market capitalization of approximately ₹7,751 Crore, trading at ₹3403.50 on the BSE. Market cap moves with the live share price.
What is Sanofi India's P/E ratio?
Sanofi India's trailing twelve-month P/E ratio is 25.3x, with a price-to-book (P/B) of 10.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Sanofi India?
Sanofi India runs a net profit margin of 17.5%, a gross margin of 40.9%, and an operating margin of 27.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Sanofi India generate?
Sanofi India reported revenue of ₹1,837 Crore for fiscal year 2025, with net income of ₹327 Crore and earnings per share (EPS) of 141.85. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Sanofi India pay a dividend?
Sanofi India offers a trailing dividend yield of about 3.6%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Sanofi India financially healthy?
Sanofi India carries a debt-to-equity ratio of 0.02x and a current ratio of 1.63x, with a market beta of 0.16. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Sanofi India a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Sanofi India (SANOFI) the key facts are: market cap ₹7,751 Crore, P/E 25.3x, revenue ₹1,837 Crore, 52-week range 3057.6-5962.4. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Sanofi India's full fundamentals live
Get Sanofi India's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.